We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Lilly (LLY) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Read MoreHide Full Article
The upcoming report from Eli Lilly (LLY - Free Report) is expected to reveal quarterly earnings of $2.46 per share, indicating an increase of 17.7% compared to the year-ago period. Analysts forecast revenues of $8.86 billion, representing an increase of 21.4% year over year.
The consensus EPS estimate for the quarter has been revised 0.6% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
That said, let's delve into the average estimates of some Lilly metrics that Wall Street analysts commonly model and monitor.
It is projected by analysts that the 'Net Sales- Cyramza (Ramucirumab /IMC-1121B)- Total' will reach $264.63 million. The estimate suggests a change of -4.7% year over year.
The consensus among analysts is that 'Net Sales- Humulin [$M]' will reach $200.52 million. The estimate indicates a year-over-year change of -14.3%.
The average prediction of analysts places 'Net Sales- Humalog [$M]' at $428.93 million. The estimate indicates a year-over-year change of -21.8%.
The collective assessment of analysts points to an estimated 'Net Sales- Forteo [$M]' of $134.02 million. The estimate suggests a change of -16.2% year over year.
Analysts forecast 'Net Sales- Cyramza (Ramucirumab /IMC-1121B) - US' to reach $98.55 million. The estimate indicates a year-over-year change of +7%.
The consensus estimate for 'Net Sales- International-Humalog [$M]' stands at $201.73 million. The estimate indicates a year-over-year change of -5%.
Analysts predict that the 'Net Sales- International-Forteo [$M]' will reach $41.19 million. The estimate suggests a change of -23.9% year over year.
Analysts expect 'Net Sales- US-Humulin [$M]' to come in at $143.49 million. The estimate indicates a year-over-year change of -14.5%.
Based on the collective assessment of analysts, 'Net Sales- US-Humalog [$M]' should arrive at $227.21 million. The estimate indicates a year-over-year change of -32.4%.
The combined assessment of analysts suggests that 'Net Sales- US-Forteo [$M]' will likely reach $92.83 million. The estimate points to a change of -12.3% from the year-ago quarter.
According to the collective judgment of analysts, 'Net Sales- US-Alimta [$M]' should come in at $16.22 million. The estimate indicates a change of -69.5% from the prior-year quarter.
Analysts' assessment points toward 'Geographic Revenue- United States' reaching $5.98 billion. The estimate indicates a year-over-year change of +28.3%.
Lilly shares have witnessed a change of +4.5% in the past month, in contrast to the Zacks S&P 500 composite's +1.6% move. With a Zacks Rank #3 (Hold), LLY is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Lilly (LLY) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
The upcoming report from Eli Lilly (LLY - Free Report) is expected to reveal quarterly earnings of $2.46 per share, indicating an increase of 17.7% compared to the year-ago period. Analysts forecast revenues of $8.86 billion, representing an increase of 21.4% year over year.
The consensus EPS estimate for the quarter has been revised 0.6% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
That said, let's delve into the average estimates of some Lilly metrics that Wall Street analysts commonly model and monitor.
It is projected by analysts that the 'Net Sales- Cyramza (Ramucirumab /IMC-1121B)- Total' will reach $264.63 million. The estimate suggests a change of -4.7% year over year.
The consensus among analysts is that 'Net Sales- Humulin [$M]' will reach $200.52 million. The estimate indicates a year-over-year change of -14.3%.
The average prediction of analysts places 'Net Sales- Humalog [$M]' at $428.93 million. The estimate indicates a year-over-year change of -21.8%.
The collective assessment of analysts points to an estimated 'Net Sales- Forteo [$M]' of $134.02 million. The estimate suggests a change of -16.2% year over year.
Analysts forecast 'Net Sales- Cyramza (Ramucirumab /IMC-1121B) - US' to reach $98.55 million. The estimate indicates a year-over-year change of +7%.
The consensus estimate for 'Net Sales- International-Humalog [$M]' stands at $201.73 million. The estimate indicates a year-over-year change of -5%.
Analysts predict that the 'Net Sales- International-Forteo [$M]' will reach $41.19 million. The estimate suggests a change of -23.9% year over year.
Analysts expect 'Net Sales- US-Humulin [$M]' to come in at $143.49 million. The estimate indicates a year-over-year change of -14.5%.
Based on the collective assessment of analysts, 'Net Sales- US-Humalog [$M]' should arrive at $227.21 million. The estimate indicates a year-over-year change of -32.4%.
The combined assessment of analysts suggests that 'Net Sales- US-Forteo [$M]' will likely reach $92.83 million. The estimate points to a change of -12.3% from the year-ago quarter.
According to the collective judgment of analysts, 'Net Sales- US-Alimta [$M]' should come in at $16.22 million. The estimate indicates a change of -69.5% from the prior-year quarter.
Analysts' assessment points toward 'Geographic Revenue- United States' reaching $5.98 billion. The estimate indicates a year-over-year change of +28.3%.
View all Key Company Metrics for Lilly here>>>
Lilly shares have witnessed a change of +4.5% in the past month, in contrast to the Zacks S&P 500 composite's +1.6% move. With a Zacks Rank #3 (Hold), LLY is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>